Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.44 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.36 |
| ▸ | HEXA | P06865 | 1/20 | 0.35 |
| ▸ | HEXB | P07686 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739564 | 0.80 | DAO (0.53) | MPOHAVCR2CYP1A2MEN1KMT2A | |
| SCHEMBL2084761 | 0.79 | ADORA3 (0.42) | CYP1A2MEN1KMT2ADRD2DRD3 | |
| SCHEMBL3746600 | 0.78 | CYP1A2 (0.39) | CYP1A2MEN1KMT2AALDH1A1HTR1A | |
| SCHEMBL3207595 | 0.78 | KDM4E (0.39) | CYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL3199526 | 0.78 | PDE4A (0.35) | MPOHAVCR2MEN1KMT2AALDH1A1 | |
| SCHEMBL8471506 | 0.73 | CYP1A2 (0.43) | CYP1A2MEN1KMT2ARAB9ADRD2 | |
| SCHEMBL3210120 | 0.73 | KDM4E (0.49) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4419395 | 0.72 | MEN1 (0.63) | MPOHAVCR2CYP1A2MEN1KMT2A | |
| SCHEMBL8471574 | 0.71 | CYP1A2 (0.41) | CYP1A2MEN1KMT2ADRD2DRD3 | |
| SCHEMBL8471302 | 0.71 | CYP1A2 (0.41) | CYP1A2MEN1KMT2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | MPO 3115/4885HAVCR2 2191/4885CYP1A2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.